English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.79 |
| Open | 0.79 |
| 1-Year Change | -37.3% |
| Day's Range | 0.78 - 0.8 |
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.
BRIEF: For the fiscal year ended 31 December 2021, Viracta Therapeutics Inc revenues decreased from $120K to $0K. Net loss increased from $21.6M to $114.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 85% to $21.7M (expense), Stock-based Compensation in SGA increase from $530K to $3.4M (expense).
Common Stock $.0001 Par, $400M. auth., 04/11, 46,027,474 issd. Insiders own 6.84%. IPO: 9/05, 6M shs. @ $7 by LehmanBrothers. 02/11, 1-for-6 reverse stock split. Preferred Stock $.0001 Par, $10M. auth., 12/10, 0 issd.
